{"id":"W4417156840","doi":"10.1056/nejmoa2514663","title":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"Johnson and Johnson","keywords":"Daratumumab; Multiple myeloma; Refractory (planetary science); Progression-free survival; Overall survival; Chemoimmunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001139768,0.0002657302,0.0009617519,0.0003366766,0.0002079678,0.0004000122,0.0002769777,0.0002994835,0.00185989],"category_scores_gemma":[0.0008327822,0.0001055587,0.0006093413,0.0003152863,0.0002361383,0.0001822621,0.0002191324,0.0006995651,0.0002817857],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005176609,"about_ca_system_score_gemma":0.0005234049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003833647,"about_ca_topic_score_gemma":0.001413051,"domain_scores_codex":[0.9995658,0.0002292843,0.0000466957,0.00005451102,0.00007224513,0.00003150361],"domain_scores_gemma":[0.9996471,0.0001037774,0.0001172017,0.00001970627,0.00002406398,0.00008807949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3868411,0.00406979,0.01142566,0.003264419,0.003594524,0.000347094,0.0001374441,0.001569065,0.01960812,0.0002878002,0.003642108,0.5652128],"study_design_scores_gemma":[0.5573413,0.3025385,0.09002634,0.000858808,0.005395439,0.0024622,0.000103183,0.003279413,0.01127896,0.0006695656,0.02600182,0.00004452025],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9526408,0.0429837,0.0003573476,0.0006365715,0.0003019743,0.0004529213,0.0002759339,0.00006483663,0.00228603],"genre_scores_gemma":[0.9906129,0.007378868,0.0005006924,0.0004491784,0.0001465682,0.0001522525,0.0002101103,0.000005814812,0.0005436754],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00185989,"threshold_uncertainty_score":0.00622201,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03293884961373357,"score_gpt":0.3410807698555924,"score_spread":0.3081419202418588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}